ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Celltrion, Johnson & Johnson and Takeda side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Celltrion×Johnson & Johnson×Takeda×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

CelltrionJohnson & JohnsonTakeda
studies on the registry843,7091,754
open to participants now414686
phase 3 studies under way59544
reach primary completion within a year68747
programswith a study of their own in two years1556+4 named only25

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseCelltrionJohnson & JohnsonTakeda
Phase 1

Celltrion: 6 of its 15 programs at phase 1

  1. ixekizumabphase 1
  2. L03RD1phase 1
  3. L03RD2phase 1
  4. CT-P52phase 1
  5. CTL02phase 1

and 1 more — sign in to see them all

40%

Johnson & Johnson: 26 of its 56 programs at phase 1

  1. Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543phase 1
  2. Anti-PSMA Antibody-drug Conjugate ARX517phase 1
  3. JNJ-86974680phase 1
  4. JNJ-87801493phase 1
  5. JNJ-64264681phase 1

and 21 more — sign in to see them all

46%

Takeda: 1 of its 25 programs at phase 1

  1. TAK-781phase 1
4%
Phase 200%

Johnson & Johnson: 8 of its 56 programs at phase 2

  1. JNJ-95597528phase 2
  2. anvatabart opadotinphase 2
  3. fludarabinephase 2
  4. JNJ-64042056phase 2
  5. JNJ-88545223phase 2

and 3 more — sign in to see them all

14%

Takeda: 5 of its 25 programs at phase 2

  1. rusfertidephase 2
  2. Anti-CCR8 Antibody-drug Conjugate TAK-188phase 2
  3. Anti-PD-L1/Anti-Vd1 T-cell Engager TAK-505phase 2
  4. TAK-411phase 2
  5. TAK-951phase 2
20%
Phase 3

Celltrion: 9 of its 15 programs at phase 3

  1. CT-P55phase 3
  2. CT-P51phase 3
  3. daratumumabphase 3
  4. empagliflozinphase 3
  5. CT-P43phase 3

and 4 more — sign in to see them all

60%

Johnson & Johnson: 18 of its 56 programs at phase 3

  1. amivantamabphase 3
  2. nipocalimabphase 3
  3. ramantamigphase 3
  4. icotrokinraphase 3
  5. lumateperonephase 3

and 13 more — sign in to see them all

32%

Takeda: 11 of its 25 programs at phase 3

  1. zasocitinibphase 3
  2. elriterceptphase 3
  3. mezagitamabphase 3
  4. TAK-360phase 3
  5. TAK-003phase 3

and 6 more — sign in to see them all

44%
Approved, new studies00%

Johnson & Johnson: 4 of its 56 programs at approved, new studies

  1. guselkumabapproved, new study
  2. teclistamabapproved, new study
  3. ibrutinibapproved, new study
  4. Esketamineapproved, new study
7%

Takeda: 8 of its 25 programs at approved, new studies

  1. Immunoglobulins, Intravenousapproved, new study
  2. Brentuximab Vedotinapproved, new study
  3. Vinblastineapproved, new study
  4. Vortioxetineapproved, new study
  5. antihemophilic factor, human recombinantapproved, new study

and 3 more — sign in to see them all

32%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Celltrion3 readouts · 3 phase 3·

Celltrion, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. empagliflozinphase 3 · Dec 0 · NCT07093476
·

Celltrion, Feb ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. CT-P51phase 3 · Feb 0 · NCT06939595

Celltrion, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. daratumumabphase 3 · Mar 8 · NCT06952478
·······
Johnson & Johnson25 readouts · 8 phase 3·

Johnson & Johnson, Dec ’26: 9 programs whose next study reaches primary completion, 4 in phase 3

  1. anvatabart opadotinphase 2 · Dec 0 · NCT04829604
  2. milvexianphase 3 · Dec 8 · NCT05757869
  3. JNJ-89862175phase 1 · Dec 15 · NCT07223125
  4. nipocalimabphase 3 · Dec 15 · NCT05327114
  5. JNJ-64042056phase 2 · Dec 22 · NCT06544616

and 4 more — sign in to see them all

Johnson & Johnson, Jan ’27: 1 program whose next study reaches primary completion

  1. JNJ-86974680phase 1 · Jan 7 · NCT07319871

Johnson & Johnson, Feb ’27: 4 programs whose next study reaches primary completion, 3 in phase 3

  1. guselkumabapproved, new study · Feb 10 · NCT06260163
  2. icotrokinraphase 3 · Feb 10 · NCT06807424
  3. lazertinibphase 3 · Feb 12 · NCT04077463
  4. teclistamabapproved, new study · Feb 12 · NCT07030517

Johnson & Johnson, Mar ’27: 3 programs whose next study reaches primary completion

  1. Anti-ENPP3/Anti-CD3 Bispecific Antibody JNJ-87890387phase 1 · Mar 16 · NCT06178614
  2. deulumateperonephase 3 · Mar 16 · NCT06480383
  3. pasritamigphase 3 · Mar 31 · NCT04898634

Johnson & Johnson, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. lumateperonephase 3 · Apr 5 · NCT05850689
  2. ramantamigphase 3 · Apr 19 · NCT05652335
·

Johnson & Johnson, Jun ’27: 4 programs whose next study reaches primary completion

  1. Anti-CALRmut/Anti-CD3 Bispecific Antibody JNJ-88549968phase 1 · Jun 14 · NCT06150157
  2. Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401phase 3 · Jun 21 · NCT06095089
  3. Aticaprantphase 3 · Jun 21 · NCT07615426
  4. JNJ-88545223phase 2 · Jun 28 · NCT07321873
·

Johnson & Johnson, Aug ’27: 1 program whose next study reaches primary completion

  1. JNJ-90189892phase 1 · Aug 5 · NCT06651229
·

Johnson & Johnson, Oct ’27: 1 program whose next study reaches primary completion

  1. JNJ-88998377phase 1 · Oct 29 · NCT06470438
Takeda7 readouts · 4 phase 3

Takeda, Nov ’26: 1 program whose next study reaches primary completion

  1. TAK-360phase 3 · Nov 30 · NCT06952699

Takeda, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. oveporextonphase 3 · Dec 17 · NCT07363720
·

Takeda, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zasocitinibphase 3 · Feb 5 · NCT07244263
  2. teduglutidephase 3 · Feb 10 · NCT06973304

Takeda, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. apadamtase alfaphase 3 · Mar 16 · NCT04683003

Takeda, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. TAK-003phase 3 · Apr 14 · NCT06579755
·····

Takeda, Oct ’27: 1 program whose next study reaches primary completion

  1. rusfertidephase 2 · Oct 28 · NCT07648030
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Celltrion

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Johnson & Johnson

New programs 1

Reached a new phase 2

Study stopped 0

None

Primary completion later 3

Takeda

New programs 1

  • TAK-664approved, new study · first study · Aug 26 · Primary Immunodeficiency Diseases

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

Where they overlap

Conditions where at least two of them have programs: 22 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionCelltrionJohnson & JohnsonTakeda
Multiple Myelomaall three · compare here

Celltrion in Multiple Myeloma: 1 program

  1. daratumumabphase 3

Their studies: Celltrion’s studies of Multiple Myeloma in search

Johnson & Johnson in Multiple Myeloma: 6 programs

  1. ramantamigphase 3
  2. fludarabinephase 2
  3. JNJ-102299639phase 1
  4. JNJ-87562761phase 1
  5. teclistamabapproved, new study

and 1 more — sign in to see them all

Their studies: Johnson & Johnson’s studies of Multiple Myeloma in search

Takeda in Multiple Myeloma: 1 program

  1. mezagitamabphase 3

Their studies: Takeda’s studies of Multiple Myeloma in search

Psoriasisall three · compare here

Celltrion in Psoriasis: 3 programs

  1. CT-P55phase 3
  2. CT-P43phase 3
  3. ixekizumabphase 1

Their studies: Celltrion’s studies of Psoriasis in search

Johnson & Johnson in Psoriasis: 3 programs

  1. icotrokinraphase 3
  2. risankizumabphase 3
  3. guselkumabapproved, new study

Their studies: Johnson & Johnson’s studies of Psoriasis in search

Takeda in Psoriasis: 1 program

  1. zasocitinibphase 3

Their studies: Takeda’s studies of Psoriasis in search

Arthritis, Psoriaticall three · compare here

Celltrion in Arthritis, Psoriatic: 1 program

  1. ixekizumabphase 1

Their studies: Celltrion’s studies of Arthritis, Psoriatic in search

Johnson & Johnson in Arthritis, Psoriatic: 4 programs

  1. icotrokinraphase 3
  2. risankizumabphase 3
  3. JNJ-88545223phase 2
  4. guselkumabapproved, new study

Their studies: Johnson & Johnson’s studies of Arthritis, Psoriatic in search

Takeda in Arthritis, Psoriatic: 1 program

  1. zasocitinibphase 3

Their studies: Takeda’s studies of Arthritis, Psoriatic in search

Carcinoma, Non-Small-Cell Lung2 of 3 · compare here

Celltrion in Carcinoma, Non-Small-Cell Lung: 1 program

  1. CT-P51phase 3

Their studies: Celltrion’s studies of Carcinoma, Non-Small-Cell Lung in search

Johnson & Johnson in Carcinoma, Non-Small-Cell Lung: 6 programs

  1. amivantamabphase 3
  2. lazertinibphase 3
  3. hafnium oxidephase 3
  4. anvatabart opadotinphase 2
  5. olomorasibphase 2

and 1 more — sign in to see them all

Their studies: Johnson & Johnson’s studies of Carcinoma, Non-Small-Cell Lung in search

–
Crohn Disease2 of 3 · compare here–

Johnson & Johnson in Crohn Disease: 4 programs

  1. icotrokinraphase 3
  2. JNJ-78934804phase 3
  3. risankizumabphase 3
  4. guselkumabapproved, new study

Their studies: Johnson & Johnson’s studies of Crohn Disease in search

Takeda in Crohn Disease: 3 programs

  1. zasocitinibphase 3
  2. teduglutidephase 3
  3. ontamalimabphase 3

Their studies: Takeda’s studies of Crohn Disease in search

Prostatic Neoplasms2 of 3 · compare here–

Takeda in Prostatic Neoplasms: 1 program

  1. Immunoglobulin Gapproved, new study

Their studies: Takeda’s studies of Prostatic Neoplasms in search

Depressive Disorder, Major2 of 3 · compare here–

Johnson & Johnson in Depressive Disorder, Major: 5 programs

  1. lumateperonephase 3
  2. seltorexantphase 3
  3. Aticaprantphase 3
  4. JNJ-89495120phase 2
  5. Esketamineapproved, new study

Their studies: Johnson & Johnson’s studies of Depressive Disorder, Major in search

Takeda in Depressive Disorder, Major: 1 program

  1. Vortioxetineapproved, new study

Their studies: Takeda’s studies of Depressive Disorder, Major in search

Colitis, Ulcerative2 of 3 · compare here–

Johnson & Johnson in Colitis, Ulcerative: 4 programs

  1. icotrokinraphase 3
  2. JNJ-78934804phase 3
  3. risankizumabphase 3
  4. guselkumabapproved, new study

Their studies: Johnson & Johnson’s studies of Colitis, Ulcerative in search

Takeda in Colitis, Ulcerative: 1 program

  1. ontamalimabphase 3

Their studies: Takeda’s studies of Colitis, Ulcerative in search

Alzheimer Disease2 of 3 · compare here–

Johnson & Johnson in Alzheimer Disease: 3 programs

  1. lumateperonephase 3
  2. seltorexantphase 3
  3. JNJ-64042056phase 2

Their studies: Johnson & Johnson’s studies of Alzheimer Disease in search

Takeda in Alzheimer Disease: 1 program

  1. Immunoglobulin Gapproved, new study

Their studies: Takeda’s studies of Alzheimer Disease in search

Arthritis, Rheumatoid2 of 3 · compare here

Celltrion in Arthritis, Rheumatoid: 2 programs

  1. CT-P13 SC Auto-Injectorphase 3
  2. ixekizumabphase 1

Their studies: Celltrion’s studies of Arthritis, Rheumatoid in search

Johnson & Johnson in Arthritis, Rheumatoid: 1 program

  1. nipocalimabphase 3

Their studies: Johnson & Johnson’s studies of Arthritis, Rheumatoid in search

–
Precursor Cell Lymphoblastic Leukemia-Lymphoma2 of 3 · compare here

Celltrion in Precursor Cell Lymphoblastic Leukemia-Lymphoma: 1 program

  1. daratumumabphase 3

Their studies: Celltrion’s studies of Precursor Cell Lymphoblastic Leukemia-Lymphoma in search

Johnson & Johnson in Precursor Cell Lymphoblastic Leukemia-Lymphoma: 2 programs

  1. bleximenibphase 3
  2. fludarabinephase 2

Their studies: Johnson & Johnson’s studies of Precursor Cell Lymphoblastic Leukemia-Lymphoma in search

–
Renal Insufficiency2 of 3 · compare here–

Johnson & Johnson in Renal Insufficiency: 2 programs

  1. seltorexantphase 3
  2. olomorasibphase 2

Their studies: Johnson & Johnson’s studies of Renal Insufficiency in search

Takeda in Renal Insufficiency: 1 program

  1. teduglutidephase 3

Their studies: Takeda’s studies of Renal Insufficiency in search

Show all 22

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetCelltrionJohnson & JohnsonTakeda
CD38daratumumabrule–mezagitamabrule
SLC6A4–lumateperoneruleVortioxetinerule
A target, or a pathogen for a vaccine, known for: Celltrion 6 of 15 · Johnson & Johnson 33 of 56 · Takeda 12 of 25 programs (36 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Johnson & Johnson: 4).